MTOR and colorectal cancer: Mitochondria-targeted drugs such as mitochondria-targeted carboxy-proxyl (Mito-CP) and mitochondrial targeting of metformin (Mito-metformin) have also been shown to induce mitophagy by releasing ULK1 from mammalian (mechanistic) target of rapamycin (mTOR) inhibition and lowering mitochondrial membrane potential, ultimately leading to reduced proliferation of colorectal cancer cells [192].